Retatrutide in Australia: is it legal, approved or available yet?

Is retatrutide approved anywhere yet?

No regulator has approved retatrutide as of 14 October 2026, according to the two records that address it most directly. The TGA stated on 14 September 2026 that retatrutide has not been approved by the TGA or any comparable international regulator. Eli Lilly describes retatrutide as investigational. Lilly says it plans to submit a Biologics License Application, the request a company files to ask the FDA to license a medicine, in the first quarter of 2027 (Lilly press release, 29 September 2026). Neither record gives an approval date.

Lilly's Phase 3 programme, called TRIUMPH, began in 2023 and had enrolled more than 5,800 participants by 29 September 2026, according to the sponsor (Lilly press release, 29 September 2026). A Phase 3 trial is a large, late-stage study. The earlier Phase 2 trial of 338 adults with obesity appeared in the New England Journal of Medicine in 2023 (Jastreboff et al.). How long retatrutide has been studied lays out the full timeline.

Positive trial results are not an approval. A regulator reviews the whole data package, including how the medicine is made. On 23 July 2026 Lilly said it was still completing the Chemistry, Manufacturing, and Controls data package that the US application needs (Lilly press release, 23 July 2026).

Evidence limits

What can this page not tell you about retatrutide's legal status?

A missing entry in a search is not proof that no rule applies. Scheduling under the Poisons Standard, approval by the TGA and state or territory law are three separate questions. The Australian law hub explains how to read each one.

Is retatrutide legal in Australia?

Retatrutide has not been approved by the TGA, and the TGA treats retatrutide products accessed outside clinical trials as unapproved therapeutic goods. The TGA names retatrutide among its examples of unapproved peptide products (TGA advisory, 13 April 2026). It states that the supply and advertising of unapproved therapeutic goods in Australia is prohibited unless a relevant exemption applies, and that any retatrutide product accessed outside clinical trials 'could be a counterfeit product' (TGA safety alert, 14 September 2026). The TGA lists infringement notices, direction or prevention notices, and civil or criminal penalties as possible consequences of non-compliance.

The October 2026 Poisons Standard, F2026L01327, is in force from 1 October 2026. Its full text holds no individual entry for retatrutide or for the research code LY3437943 (searched 14 October 2026). A missing entry is not a permission, and a medicine approved for supply is recorded as an entry on the ARTG (Australian Register of Therapeutic Goods), which is a separate question from scheduling. The TGA states that retatrutide has not been approved (TGA safety alert, 14 September 2026), and Sport Integrity Australia's retatrutide page says the same, and adds that retatrutide is not listed on the 2026 WADA Prohibited List (both checked 14 October 2026). The 2026 List's class S0 covers any pharmacological substance that no section of the List addresses and that has no current governmental approval for human therapeutic use (WADA Prohibited List 2026, page 4), so a missing name does not establish that a substance is permitted in sport. The instrument also reaches derivatives and preparations of named substances, so a name search cannot settle every group question.

Lilly's own wording is direct. Its press release of 29 September 2026 states: 'Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.' The TGA adds that a 'research use only' disclaimer 'does not make its supply lawful' (TGA advisory, 13 April 2026). Retatrutide in Perth records the Western Australian side of the same question.

Is retatrutide FDA approved?

Retatrutide is not FDA approved as of 14 October 2026. Eli Lilly says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027 (Lilly press release, 29 September 2026). FDA warning letter 734884, dated 24 August 2026, lists 'Retatrutide' among products offered by an online seller and states that no approved application is in effect for them, so the FDA calls them unapproved new drugs. The letter is about that seller's products, not a ruling on Lilly's own programme.

The same letter takes up labels. It says that, despite product labels stating 'for research use only', evidence from the seller's website established that the products were intended to be drugs for human use (FDA warning letter 734884, 24 August 2026).

The US has one more record. Lilly's ClinicalTrials.gov entry NCT07629401, titled 'Pre-approval Expanded Access of Retatrutide', shows status 'Available' and was last updated on 6 August 2026 (checked 14 October 2026). It describes single-patient pre-approval access for adults with severe obesity and serious complications who cannot join a trial. It lists no Australian site, so it establishes nothing about access in Australia.

When will retatrutide be available in Australia?

No source checked gives an Australian availability date for retatrutide, and none says it will be approved in 2026. Eli Lilly says it is completing the manufacturing data package for a US application planned for the first quarter of 2027 (Lilly press release, 23 July 2026, repeated in the 29 September 2026 release). The TGA's legislative timeframe for a new medicine application is 255 working days, and its priority review pathway has a 150-working-day target (TGA, checked 14 October 2026). Those periods apply only once an application exists, and no source checked reports one for retatrutide.

Lilly said in its press release of 23 July 2026 that it now has 'the clinical data package to support global submissions' for obesity, knee osteoarthritis pain and obstructive sleep apnoea. That sentence is a statement about the data. It names no country and no date for any submission outside the US.

Three dated events set the pace. On 23 July 2026 Lilly reported topline results from two Phase 3 trials, TRIUMPH-2 and TRIUMPH-3. On 14 September 2026 the TGA issued its retatrutide safety alert. On 29 September 2026 Lilly presented detailed TRIUMPH-2 results at a European diabetes meeting, and the paper appeared in The Lancet (Bellido et al., 2026).

Approval and availability are also different facts, because an approved medicine still has to be supplied. How retatrutide differs from Mounjaro and Ozempic compares retatrutide's record with two approved medicines.

Is retatrutide available in Australia through clinical trials?

Retatrutide has been studied at Australian sites, but a trial listing is not a supply route. ClinicalTrials.gov, checked on 14 October 2026, returns 34 retatrutide records, and six name Australian sites. They include TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079) and TRIUMPH-3 (NCT05882045). Five of the six list Western Australian sites at Nedlands, Joondalup or Murdoch. Registry entries show where a trial ran and what its status was at the last update. Each record sets out who may take part under its own protocol, and this page is not an invitation to enrol.

Registry status differs by record. As of each record's last update, NCT05929066, NCT05929079, NCT05882045 and NCT05931367 (a trial in obesity with knee osteoarthritis) are completed. NCT06383390, a cardiovascular and kidney outcomes trial, is active but not recruiting. NCT07165028, a liver disease outcomes master protocol, is recruiting and lists Fiona Stanley Hospital at Murdoch.

TRIUMPH-2 ran at 92 medical and research centres and hospitals across eight countries and randomly assigned 1152 adults with obesity and type 2 diabetes (Bellido et al., The Lancet, 2026).

What has the TGA reported about retatrutide products sold online?

Four dated TGA records name retatrutide. On 13 April 2026 the TGA listed it among unapproved peptide product examples, and on 19 June 2026 the TGA and the Chief Medical Officer repeated that list. On 4 August 2026 the TGA executed search warrants in New South Wales and seized products that included retatrutide (TGA media release, 17 August 2026). On 14 September 2026 the TGA reported that laboratory testing of one product sold as retatrutide found undeclared semaglutide and no retatrutide, a finding about that single sample that does not show how common mislabelled products are (TGA safety alert, 14 September 2026). The four records are an advisory, a joint statement, a seizure and a laboratory test, each with its own date.

The 14 September 2026 alert followed one consumer's report of a serious adverse effect: uncontrollable vomiting that caused a torn oesophagus and needed hospital treatment, and a single report cannot show how common such events are (TGA safety alert, 14 September 2026). In the one sample the TGA obtained, held in its original unmarked vial, laboratory testing found semaglutide at about eight times the level found in semaglutide products assessed by the TGA and on the ARTG, a result for that sample only (TGA safety alert, 14 September 2026).

The alert describes one product and one report, so it cannot show how common mislabelled retatrutide is. This site's retatrutide reference material listing is a laboratory reference listing. It does not change anything the TGA has stated above, and it is not an approval or a claim of legality.